IRTC iRhythm Holdings, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1388658 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY21.6%
TTM net income YoY25.0%
TTM EPS YoY27.3%
Revenue 3-yr CAGR21.8%
Net income 3-yr CAGR—
Margins
Gross margin72.3%
Operating margin-5.7%
Net margin-4.5%
FCF margin0.9%
EBITDA margin-3.3%
Returns
ROE-25.8%
ROA-3.7%
ROIC (approx.)—
Asset turnover0.82x
Leverage & solvency
Liabilities / assets83.8%
Debt / equity0.00x
Current ratio3.57x
Interest coverage-3.71x
Cash quality & payout
Operating cash flow / net income-1.44x
Accruals ratio-9.0%
Payout ratio—
Capex / revenue5.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $221.59M | $224.17M | $199.39M | $208.89M | $192.88M | $186.69M | $158.68M | $164.32M |
| Cost of revenue | $57.10M | $60.97M | $58.04M | $60.84M | $55.76M | $53.83M | $49.46M | $49.26M |
| Gross profit | $164.49M | $163.21M | $141.35M | $148.06M | $137.12M | $132.86M | $109.22M | $115.07M |
| R&D expense | $20.60M | $19.84M | $21.36M | $21.05M | $21.03M | $21.01M | $21.52M | $19.08M |
| SG&A expense | $125.64M | $131.66M | $135.88M | $122.00M | $124.22M | $126.38M | $119.96M | $99.77M |
| Operating income | -$32.55M | -$2.54M | -$16.18M | $2.29M | -$8.43M | -$18.71M | -$32.56M | -$4.08M |
| Interest expense | $3.30M | $3.29M | $3.29M | $3.32M | $3.28M | $3.28M | $3.27M | $3.32M |
| Pretax income | -$29.85M | -$381,000 | -$13.43M | $6.03M | -$5.19M | -$14.40M | -$30.04M | -$1.18M |
| Income tax | $0 | $0 | $500,000 | $447,000 | $24,000 | -$183,000 | $665,000 | $151,000 |
| Net income | -$29.85M | -$381,000 | -$13.93M | $5.58M | -$5.21M | -$14.22M | -$30.70M | -$1.33M |
| EBITDA | -$27.25M | $2.66M | -$11.19M | $7.49M | -$3.23M | -$13.61M | -$27.36M | $1.22M |
| EPS (basic) | -0.90 | -0.01 | -0.43 | — | -0.16 | -0.44 | -0.97 | — |
| EPS (diluted) | -0.90 | -0.01 | -0.43 | — | -0.16 | -0.44 | -0.97 | — |
| Weighted avg. shares (diluted) | 33.10M | 32.90M | 32.51M | — | 32.17M | 31.99M | 31.59M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $394.72M | $246.68M | $240.15M | $236.01M | $255.60M | $309.11M | $375.28M | $427.95M |
| Short-term investments | $166.00M | $344.60M | $309.47M | $347.75M | $309.61M | $236.44M | $145.31M | $115.96M |
| Receivables | $81.13M | $84.27M | $80.86M | $75.71M | $76.16M | $82.15M | $80.64M | $79.94M |
| Inventory | $23.22M | $22.51M | $23.80M | $21.63M | $19.56M | $18.40M | $14.34M | $14.04M |
| Current assets | $730.21M | $755.95M | $680.56M | $702.76M | $680.03M | $663.92M | $636.01M | $645.82M |
| PP&E, net | $176.94M | $165.31M | $156.70M | $151.60M | $149.32M | $139.70M | $130.85M | $125.09M |
| Goodwill | $862,000 | $862,000 | $862,000 | $862,000 | $862,000 | $862,000 | $862,000 | $862,000 |
| Total assets | $1.09B | $1.09B | $1.01B | $1.02B | $995.21M | $964.03M | $926.10M | $931.45M |
| Current liabilities | $204.73M | $196.10M | $131.75M | $151.89M | $146.91M | $132.21M | $111.34M | $110.92M |
| Total liabilities | $914.34M | $907.44M | $845.15M | $867.30M | $873.32M | $860.37M | $839.43M | $840.54M |
| Shareholders' equity | $177.11M | $185.98M | $161.21M | $152.75M | $121.89M | $103.66M | $86.67M | $90.91M |
| Shares outstanding | 33.19M | 32.94M | 32.85M | 32.30M | 32.20M | 32.10M | 31.91M | 31.39M |
| Cash flow statement | ||||||||
| Operating cash flow | $4.44M | $51.08M | -$26.17M | $26.21M | $34.88M | $27.66M | -$7.89M | $19.23M |
| Capital expenditure | $15.98M | $13.56M | $6.91M | $11.72M | $14.83M | $10.37M | $9.42M | $6.84M |
| Free cash flow | -$11.54M | $37.52M | -$33.08M | $14.49M | $20.05M | $17.29M | -$17.31M | $12.39M |
| Investing cash flow | $153.20M | -$48.64M | $30.21M | -$48.80M | -$89.20M | -$100.92M | -$38.14M | -$122.16M |
| Financing cash flow | $403,000 | $4.08M | $149,000 | $2.96M | $825,000 | $7.09M | $1.73M | $2.99M |
| Depreciation & amortization | $5.30M | $5.20M | $5.00M | $5.20M | $5.20M | $5.10M | $5.20M | $5.30M |
| Stock-based compensation | $19.49M | $20.04M | $21.49M | $21.11M | $21.01M | $22.83M | $23.34M | $16.01M |
| Share buybacks | — | — | — | $0 | $0 | $0 | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.